Business
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single dose
About this update from Intellia Therapeutics, Inc.
[{"type":"text","content":"Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single dose of NTLA-2001 resulted in rapid, deep and sustained reduction in disease-causing proteinInterim readout showed treatment with NTLA-2001 at 1.0 mg/kg dose led to 93% mean and 98% maximum serum TTR reduction by day 28, with durability observed through follow-up period; initiated Part 2 in the polyneuropathy arm, with plans to share additional data from Part 1 in June 2022Expects to share initial safety and serum TTR reduction data from Part 1 of the cardiomyopathy arm for NTLA-2001 in 2H 2022 Initiated second dose-escalation cohort evaluating NTLA-2002 for hereditary angioedema (HAE); plans to present interim data in 2H 2022Dosed first patient in Phase 1/2a study for NTLA-5001, a novel investigational T cell receptor (TCR)-T cell therapy, for acute myeloid leukemia (AML)Advancing new development candidates, including NTLA-2003, NTLA-3001 and NTLA-6001, toward future regulatory submissions; on track to nominate one additional new in vivo candidate in 2022 Ended the first quarter of 2022 with strong cash position of $995 million CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2022. “Intellia is successfully executing on its 2022 strategic priorities as we advance our proprietary CRISPR-based drug discovery and development platform. We recently shared updated interim data from our landmark study of NTLA-2001, which demonstrated that treatment with NTLA-2001 in people with ATTR amyloidosis with polyneuropathy was generally well-tolerated and delivered rapid, consistent, dose-dependent reductions in serum TTR. In addition to achieving a mean reduction of 93% at the 1.0 mg/kg dose, we were particularly pleased that reductions in serum TTR levels persisted, further bolstering our confidence in NTLA-2001 as a potentially durable, one-time treatment for ATTR amyloidosis. In June, we plan to share additional durability data from the dose-escalation portion of the polyneuropathy arm and data supporting our fixed dose selectio...